Allen Widysanto Indonesia

PROFIL PROFESIONAL Prof. Dr. dr. Allen Widysanto, SpP, TTS, RPSGT, FAPSR, FISR adalah seorang Guru Besar dan pakar di bidang Pulmonologi serta Kedokteran Respirasi. Beliau memiliki keahlian mendalam dalam manajemen sepsis, infeksi saluran napas (Pneumonia), serta merupakan ahli tersertifikasi internasional dalam bidang Kedokteran Tidur (Sleep Medicine) dan Pengobatan Tembakau. Saat ini, beliau memadukan peran sebagai pendidik di FK UPH dan praktisi klinis senior di Siloam Hospitals. RIWAYAT PENDIDIKAN Dokter Umum: Fakultas Kedokteran Universitas Katolik Indonesia Atma Jaya, Jakarta (1994). Spesialis Pulmonologi & Kedokteran Respirasi (Sp.P): Departemen Pulmonologi dan Kedokteran Respirasi, Fakultas Kedokteran Universitas Indonesia (FKUI), Jakarta (2007). Doktor Ilmu Kedokteran (S3): Program Pascasarjana, Fakultas Kedokteran Universitas Hasanuddin (UNHAS), Makassar (2012). Tobacco Treatment Specialist (TTS): Mississippi University, Amerika Serikat (2014). SERTIFIKASI INTERNASIONAL & KEAHLIAN KHUSUS RPSGT (Registered Polysomnographic Technologist): Sertifikasi profesional tingkat dunia dalam teknologi tidur (Sleep Technology) dari Board of Registered Polysomnographic Technologists (ID: 19803). Berlaku hingga 12 Juni 2024. TTS (Tobacco Treatment Specialist): Tenaga ahli bersertifikat dalam intervensi klinis dan pengobatan untuk berhenti merokok. FAPSR (Fellow of the Asian Pacific Society of Respirology): Pengakuan keahlian tingkat lanjut dalam bidang respirologi di kawasan Asia Pasifik. PENGALAMAN ORGANISASI PROFESI PDPI (Perhimpunan Dokter Paru Indonesia): Anggota Bidang Hubungan Internasional Pengurus Pusat (Periode 2017). IDI (Ikatan Dokter Indonesia): Anggota Aktif. APSR (Asian Pacific Society of Respirology): Anggota Regional. ERS (European Respiratory Society): Anggota Internasional. INA-Sleep (Indonesia Society of Sleep Medicine): Anggota. Sleep Asia: Anggota. Tobacco Treatment ACT, Mississippi: Anggota. PENGHARGAAN & PRESTASI Juara Nasional Laporan Kasus Paru (National Champion of Pulmonary Case Report), 2005. Dosen Terbaik (Best Teacher) Fakultas Kedokteran Universitas Pelita Harapan, 2008. KONTRIBUSI ILMIAH & RISET UTAMA Beliau aktif dalam penelitian medis yang dipublikasikan secara internasional, dengan fokus pada: Obstructive Sleep Apnea (OSA): Meneliti hubungan antara Oxygen Desaturation Index dan Lipoprotein Phospholipase A2 terhadap risiko Penyakit Arteri Koroner pada pasien gangguan tidur. Manajemen Sepsis & Pneumonia: Studi epidemiologi sepsis pada pasien Community-acquired Pneumonia (CAP) di Siloam Hospital Karawaci (37% prevalensi dari 212 pasien). Pengembangan protokol penghentian antibiotik berdasarkan biomarker Procalcitonin (PCT) dan kriteria klinis untuk mempersingkat durasi terapi menjadi 7 hari guna menekan biaya dan efek samping. Strategi De-escalation antibiotik pada kasus Hospital-acquired Pneumonia (HAP). ---------------------------------------------------------------------------------------------------------------------------------------------------------- PROFESSIONAL PROFILE Prof. Dr. dr. Allen Widysanto, SpP, TTS, RPSGT, FAPSR, FISR is a Full Professor and distinguished expert in Pulmonology and Respiratory Medicine. She possesses profound expertise in sepsis management and respiratory tract infections (Pneumonia). Additionally, she is an internationally certified specialist in Sleep Medicine and Tobacco Treatment. Currently, she balances her roles as an educator at the Faculty of Medicine, Universitas Pelita Harapan (UPH) and a senior clinical practitioner at Siloam Hospitals. EDUCATION • Medical Doctor (M.D.): Faculty of Medicine, Universitas Katolik Indonesia Atma Jaya, Jakarta (1994). • Specialist in Pulmonology & Respiratory Medicine (Sp.P): Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia (FKUI), Jakarta (2007). • Doctor of Medical Sciences (Ph.D.): Postgraduate Program, Faculty of Medicine, Universitas Hasanuddin (UNHAS), Makassar (2012). • Tobacco Treatment Specialist (TTS): Mississippi University, United States (2014). INTERNATIONAL CERTIFICATIONS & SPECIALIZED EXPERTISE • RPSGT (Registered Polysomnographic Technologist): World class professional credential in sleep technology awarded by the Board of Registered Polysomnographic Technologists (ID: 19803; Valid through June 12, 2024). • TTS (Tobacco Treatment Specialist): Certified expert in clinical intervention and treatment strategies for smoking cessation. • FAPSR (Fellow of the Asian Pacific Society of Respirology): Advanced expertise and recognition in the field of respirology within the Asia Pacific region. PROFESSIONAL ORGANIZATIONS & AFFILIATIONS • PDPI (Indonesian Society of Respirology): Member of the International Relations Division, Central Executive Board (2017 Cohort). • IDI (Indonesian Medical Association): Active Member. • APSR (Asian Pacific Society of Respirology): Regional Member. • ERS (European Respiratory Society): International Member. • INA Sleep (Indonesian Society of Sleep Medicine): Member. • Sleep Asia: Member. • Tobacco Treatment ACT, Mississippi: Member. AWARDS & ACHIEVEMENTS • National Champion of Pulmonary Case Report, 2005. • Best Teacher Award, Faculty of Medicine, Universitas Pelita Harapan, 2008. SCIENTIFIC CONTRIBUTIONS & KEY RESEARCH Prof. Allen is actively involved in internationally published medical research, focusing primarily on: • Obstructive Sleep Apnea (OSA): Investigating the correlation between the Oxygen Desaturation Index and Lipoprotein Phospholipase A2 regarding the risk of Coronary Artery Disease in patients with sleep disorders. • Sepsis & Pneumonia Management: - An epidemiological study of sepsis in patients with Community acquired Pneumonia (CAP) at Siloam Hospital Karawaci (showing a 37% prevalence out of 212 patients). - Development of antibiotic discontinuation protocols guided by Procalcitonin (PCT) biomarkers and clinical criteria to shorten therapy duration to 7 days, aimed at reducing medical costs and adverse effects. - Antibiotic de escalation strategies in Hospital acquired Pneumonia (HAP) cases.
Job Title
Vice Dean Academic
Faculty / Department / Division
Medical Faculty
Institution / Organisation
Pelita Harapan University

19 November 2026, Thursday

Time Session
08:30
13:00
Naricha Chirakalwasan Chairperson Thailand
Rashidah Yasin Chairperson Malaysia
Function Room 8, Ground Mezzanine Floor

21 November 2026, Saturday

Time Session
11:00
12:30
Allen Widysanto Chairperson Indonesia
Rashidah Yasin Chairperson Malaysia
  • Naricha Chirakalwasan Speaker Thailand
  • Kah-Lin Choo Speaker Singapore
    Toward Personalised Non-PAP Therapy for Obstructive Sleep Apnoea While positive airway pressure (PAP) remains the gold standard treatment for obstructive sleep apnoea (OSA), long-term compliance is frequently limited by patient intolerance. Emerging insights into the pathophysiology of OSA reveal that the condition is not solely driven by anatomical airway collapse; rather, it is governed by four distinct endotypes that include three non-anatomical endotypes such as poor upper airway muscle responsiveness, low respiratory arousal threshold, and high loop gain (ventilatory control instability). This paradigm shift paves the way for precision medicine and targeted, non-PAP therapeutic strategies tailored to individual physiological profiles. This lecture will review recent advances in non-PAP therapeutic modalities mapped to specific OSA endotypes, examine clinical trial evidence, and address current challenges and future directions in clinical phenotyping and personalized care. Strategies include anti-obesity interventions such as dual GIP/GLP-1 receptor agonists and structural stabilization through hypoglossal or ansa cervicalis nerve stimulation, pharmacological neuromuscular stabilization, loop gain modulation and arousal threshold management. Personalising non-PAP therapy based on individual pathophysiological traits offers a promising paradigm for patients who refuse or are intolerant to PAP. Future clinical success relies on validating automated computational phenotyping tools within routine diagnostic workflows, standardizing prediction thresholds across diverse global populations, and establishing outcome-focused trials linked to hard clinical endpoint.
  • Winfried J. Randerath Speaker Germany
  • Q&A
Ballroom 2, Lower Ground Floor